文献速递肝肾功能剂量调整药物相互作用特殊人群用药

Atogepant预防偏头痛的群体药代动力学研究

Population Pharmacokinetics of Atogepant for the Prevention of Migraine.
PubMed 文献 · Clin Pharmacokinet · 2025-11-12

本研究基于12项1期研究、1项2b/3期研究和1项3期研究的药代动力学数据,构建了Atogepant的群体药代动力学模型,并用慢性偏头痛3期研究及难治性发作性偏头痛3期研究的数据进行外部验证。模型显示剂量、制剂、食物、肝功能、合并用药和体重对Atogepant药代动力学有显著影响,而年龄、性别、轻中度肾功能损害及多种合并用药无临床相关影响。

要点

  • 年龄、性别、体重、种族及P-gp/BCRP抑制剂等合并用药无需调整Atogepant剂量
  • 重度肝损害及伊曲康唑、奎尼丁、利福平可显著改变Atogepant清除率
  • 健康受试者与发作性或慢性偏头痛患者的Atogepant药代动力学相似

核心结论

  • Atogepant在健康受试者与慢性偏头痛或发作性偏头痛患者中的药代动力学相似。
  • 基于年龄、性别、种族、体重等内在因素或P-gp抑制剂、BCRP抑制剂等合并用药,无需调整Atogepant剂量。

研究设计与样本

  • 基于12项1期研究、1项2b/3期研究和1项3期研究的药代动力学数据构建群体药代动力学模型。
  • 用慢性偏头痛3期研究和两种至四种常规口服预防治疗失败的发作性偏头痛3期研究数据进行外部验证。
  • 采用非线性混合效应建模和诊断评估构建并评价模型。

主要发现

  • 最终模型为三室分布模型,中央室线性消除,吸收过程为序贯零级/一级滞后吸收。
  • 制剂、剂量、食物状态、肝功能、合并用药和体重均对Atogepant药代动力学有统计学显著影响。
  • 吸收受剂量和制剂影响,表观中央分布容积随体重增加,相对生物利用度随剂量轻度增加,高脂餐延长吸收滞后时间。

关键数值与推荐

  • 重度肝损害及合并伊曲康唑、奎尼丁、单剂利福平分别使表观清除率降低约37%、约66%、约29%和约13%,多剂利福平使表观清除率增加1.82倍。
  • 合并伊曲康唑和单剂利福平分别使相对生物利用度增加1.95倍和2.4倍,多剂利福平使其降低约25%。
  • 轻中度肾功能损害、合并BCRP抑制剂、BCRP底物及他汀类、年龄和性别对Atogepant药代动力学无临床相关影响。
  • 未观察到健康受试者与偏头痛患者之间Atogepant药代动力学的统计学显著差异。

临床怎么用

  • 临床使用Atogepant时一般无需因年龄、性别、体重、种族或轻中度肾功能损害调整剂量。
  • 合并P-gp抑制剂、BCRP抑制剂、口服避孕药成分、法莫替丁、埃索美拉唑、舒马曲普坦、对乙酰氨基酚或萘普生时无需调整剂量。
  • 重度肝损害或合并伊曲康唑、奎尼丁、利福平等强效相互作用药物时需关注清除率变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Atogepant is an oral calcitonin gene-related peptide receptor antagonist developed for the preventive treatment of migraine. This work aimed to develop a population pharmacokinetic (popPK) model to support dosage regimen selection during the clinical development of atogepant in patients with episodic migraine (EM) or chronic migraine (CM) and to guide the dosing recommendations for regulatory approval. METHODS: Pharmacokinetic data collected from 12 phase 1 studies, 1 phase 2b/3 study, and 1 phase 3 study in healthy participants and patients with EM were used to develop a popPK model that was externally validated with data from a CM phase 3 study and a phase 3 study in patients with EM for whom two to four classes of conventional oral preventive treatments have failed. The model was built and evaluated using nonlinear mixed-effect modeling and diagnostic assessments. RESULTS: The final model featured three disposition compartments, with linear elimination from the central compartment and a sequential zero-/first-order lagged absorption process. Formulation, dose, food status, liver function, concomitant medication, and body weight were each found to have a statistically significant influence on atogepant's pharmacokinetics. Absorption was affected by dose and formulation, the apparent central volume of distribution (V1/F) increased with body weight, relative bioavailability (Frel) modestly increased with dose, and a high-fat meal lengthened absorption lag time. Severe hepatic impairment and coadministration of itraconazole, quinidine, or a single rifampin dose decreased apparent clearance (CL/F) by ~37% and ~66%, ~29%, and ~13%, respectively, while coadministration of multiple rifampin doses increased CL/F by 1.82-fold. Frel increased by 1.95 and 2.4 fold with coadministration of itraconazole and a single rifampin dose, respectively, and decreased by ~25% with multiple rifampin doses. Mild/moderate renal impairment, coadministration of breast cancer resistance protein (BCRP) inhibitors, BCRP substrates and statins, age, and sex had no clinically relevant effect on atogepant pharmacokinetics. No statistically significant differences were observed in atogepant's pharmacokinetics between healthy participants and patients with migraine. CONCLUSIONS: The pharmacokinetics of atogepant are similar in healthy participants and patients with CM or EM. Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycoprotein (P-gp) inhibitors, BCRP inhibitors, oral contraceptive components (ethinyl estradiol and levonorgestrel), famotidine, esomeprazole, sumatriptan, acetaminophen, and naproxen are not necessary. Atogepant's popPK model provides a valuable tool for evaluating specific questions for patients, healthcare providers, and regulatory agencies. Integration into other modeling approaches has also aided in model-informed drug development decisions. CLINICAL TRIAL REGISTRATION: NCT03855137 (EudraCT number: 2018-004337-32).

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Schlachter L, Stodtmann S, Voelkner A, et al. Population Pharmacokinetics of Atogepant for the Prevention of Migraine. Clin Pharmacokinet. 2025. PMID: 41222899. doi:10.1007/s40262-025-01566-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。